Plexium: Fresh off Amgen deal, Plexium raises $102M for degrader platform
FEB 24, 2022 | 11:08 AM PST | BIOCENTURY | FINANCEFRESH OFF AMGEN DEAL, PLEXIUM RAISES $102M FOR DEGRADER PLATFORMBY BVF Partners, TCG Crossover co-lead funding to advance Plexium's cell- and DEL-based degrader discovery tech https://www.biocentury.com/article/642386/fresh-off-amgen-deal-plexium-raises-102m-for-degrader-platform© 2022 BioCentury Inc. All Rights Reserved
Read full article »
President & CEO
Michael Martin
Plexium is a California-based biotechnology company that develops a platform that provides targeted protein degradation therapies for the treatment of cancer.
Read more